IBEF: July 15, 2019
Addressing shareholders in the company's Annual Report for 2018-2019, Drug maker Lupin aims to launch its first biosimilar product and commercialise its first inhalation product in the US in the current fiscal and the new launches across the globe would help it to achieve sustainable growth, as per Lupin chief executive officer Vinita Gupta and managing director Nilesh Gupta.
The firm's first biosimilar Etanercept is approved for launch in Japan, while the European approval is awaited. As Lupin launched its 22 new products in the US market last fiscal.
Now, Lupin plan to bring its first biosimilar to market, commercialise its first inhalation product in the US, continue the growth drive in its US generics business and launch their injectables portfolio.
"With more than 157 Abbreviated New Drug Application’s (ANDAs) at present pending endorsement with the US Food and Drug Administration’s (USFDA), we have a rich pipeline tending to a total market size of over USD 52 billion”.
The Mumbai-based organization's different manufacturing plants have come under the US Food and Drug Administration’s (USFDA) scanner for different consistence issues.
Lupin’s first biosimilar Etanercept is permitted for the launch in Japan, whereas the European endorsement is awaited.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.